CRDF
Price:
$4.34
Market Cap:
$288.69M
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, ...[Read more]
Industry
Biotechnology
IPO Date
2004-07-27
Stock Exchange
NASDAQ
Ticker
CRDF
According to Cardiff Oncology, Inc.’s latest financial reports and current stock price. The company's current Dividend Yield is 0%. This represents a change of -100.00% compared to the average of 0.01% of the last 4 quarters.
The mean historical Dividend Yield of Cardiff Oncology, Inc. over the last ten years is 97.07%. The current 0% Dividend Yield has changed -100.00% with respect to the historical average. Over the past ten years (40 quarters), CRDF's Dividend Yield was at its highest in in the December 2019 quarter at 234.70%. The Dividend Yield was at its lowest in in the June 2015 quarter at 0%.
Average
97.07%
Median
22.72%
Minimum
0%
Maximum
327.23%
Discovering the peaks and valleys of Cardiff Oncology, Inc. Dividend Yield, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual Dividend Yield = 327.23%
Minimum Annual Increase = -100.00%
Minimum Annual Dividend Yield = 0%
Year | Dividend Yield | Change |
---|---|---|
2023 | 0% | -100.00% |
2022 | 0.68% | 6.53% |
2021 | 0.01% | -99.84% |
2020 | 6.45% | -98.03% |
2019 | 327.23% | 0.03% |
2018 | 327.13% | 45.09% |
2017 | 225.47% | 489.42% |
2016 | 38.25% | 123.29% |
2015 | 17.13% | -39.49% |
2014 | 28.31% | Infinity% |
The current Dividend Yield of Cardiff Oncology, Inc. (CRDF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
0.23%
5-year avg
66.87%
10-year avg
97.07%
Cardiff Oncology, Inc.’s Dividend Yield is less than Reviva Pharmaceuticals Holdings, Inc. (0%), less than eFFECTOR Therapeutics, Inc. (0%), less than PDS Biotechnology Corporation (0%), less than Navidea Biopharmaceuticals, Inc. (0%), less than Reviva Pharmaceuticals Holdings, Inc. (0%), less than Eyenovia, Inc. (0%), less than Cognition Therapeutics, Inc. (0%), less than TransCode Therapeutics, Inc. (0%), less than Kodiak Sciences Inc. (0%), less than SELLAS Life Sciences Group, Inc. (0%), less than NLS Pharmaceutics AG (0%), less than Mereo BioPharma Group plc (0%), less than Aravive, Inc. (0%), less than Day One Biopharmaceuticals, Inc. (0%), less than IN8bio, Inc. (0%), less than Cue Biopharma, Inc. (0%), less than Lantern Pharma Inc. (0%), less than Gracell Biotechnologies Inc. (0%), less than Cullinan Oncology, Inc. (0%), less than Bolt Biotherapeutics, Inc. (0%), less than Lyra Therapeutics, Inc. (0%), less than Autolus Therapeutics plc (0%),
Company | Dividend Yield | Market cap |
---|---|---|
0% | $86.64M | |
0% | $941.00 | |
0% | $66.21M | |
0% | $10.01K | |
0% | $96.73M | |
0% | $10.25M | |
0% | $31.88M | |
0% | $2.71M | |
0% | $573.60M | |
0% | $71.09M | |
0% | $4.60M | |
0% | $583.35M | |
0% | $2.95M | |
0% | $1.30B | |
0% | $18.44M | |
0% | $68.42M | |
0% | $37.96M | |
0% | $989.87M | |
0% | $751.14M | |
0% | $19.53M | |
0% | $11.82M | |
0% | $612.07M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cardiff Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cardiff Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Dividend Yield?
How can you use the Dividend Yield?
What is Cardiff Oncology, Inc.'s Dividend Yield?
How is the Dividend Yield calculated for Cardiff Oncology, Inc. (CRDF)?
What is the highest Dividend Yield for Cardiff Oncology, Inc. (CRDF)?
What is the 3-year average Dividend Yield for Cardiff Oncology, Inc. (CRDF)?
What is the 5-year average Dividend Yield for Cardiff Oncology, Inc. (CRDF)?
How does the current Dividend Yield for Cardiff Oncology, Inc. (CRDF) compare to its historical average?